Physician profile
Saba Faiz
NPI 1790994622
$7,443.81
in general payments reported to CMS, 2019-2025
26 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $101 · 2021: $37.32 · 2022: $4,527 · 2023: $308 · 2024: $631 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,450.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $4,615.49 | 2022-2025 | |
| Amgen INC. | $724.31 | 2019-2025 | Tepezza, Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $259.74 | 2019-2025 | Lokelma |
| Novo Nordisk INC | $245.89 | 2020-2025 | Wegovy |
| Lilly USA, LLC | $191.95 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.89 | 2024-2025 | Jardiance, Synjardy |
| Beta Bionics, INC. | $127.16 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sanofi-Aventis U.S. LLC | $125.00 | 2019 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Ibsa Pharma INC. | $109.94 | 2024-2025 | Tirosint, Licart, Flector |
| Ascendis Pharma Endocrinology INC | $88.97 | 2024-2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $88.51 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Acella Pharmaceuticals, LLC | $75.45 | 2024-2025 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $67.86 | 2025 | |
| Madrigal Pharmaceuticals | $67.19 | 2025 | Rezdiffra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $56.46 | 2024-2025 | |
| Corcept Therapeutics | $49.26 | 2025 | Korlym |
| Dexcom, INC. | $47.22 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $44.25 | 2025 | Unithroid |
| Abbvie INC. | $41.95 | 2025 | |
| Kyowa Kirin, INC. | $37.00 | 2025 | |
| Antares Pharma, INC. | $20.39 | 2025 | Xyosted |
| Radius Health, INC. | $19.61 | 2025 | |
| Xeris Pharmaceuticals, INC. | $18.13 | 2025 | Recorlev |
| Averitas Pharma INC. | $14.30 | 2025 | Qutenza |
| Eisai INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Faiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.